Drug therapy in Behçet's disease

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Behçet's disease presents a significant challenge in uveitis management.
• Treatment strategies for Behçet's disease require personalization due to varied presentations and regional care differences.

Purpose of the Study:

• To outline a tailored treatment approach for Behçet's disease-related uveitis.
• To discuss the progression of treatment from topical to systemic therapies and novel agents.

Main Methods:

• Review of current treatment modalities for Behçet's disease uveitis.
• Discussion of therapeutic options including corticosteroids, cyclosporin, azathioprine, chlorambucil, and interferon alfa.

Main Results:

• Anterior segment inflammation typically responds to topical corticosteroids.
• Posterior segment inflammation often necessitates systemic corticosteroids, immunosuppressants, or newer agents like interferon alfa.

Conclusions:

• A stepwise, individualized treatment plan is crucial for managing Behçet's disease uveitis.
• Further research is needed to confirm the safety and efficacy of emerging treatments such as interferon alfa.